Showing 841-850 of 1784 results for "".
The Need for Therapies to Address Postoperative Corneal Edema
https://crstoday.com/crst-supplements/the-need-for-therapies-to-address-postoperative-corneal-edema/the-need-for-therapies-to-address-postoperative-corneal-edema/45105/Acute Rupture of the Anterior Capsule
https://crstoday.com/topics/cataract-surgery/acute-rupture-of-the-anterior-capsule/44787/Options for managing a patient whose vision decreased after trabeculectomy.Roundtable: Challenging the Dogma of Fellowship Training
https://crstoday.com/crst-issues/may-2022/roundtable-challenging-the-dogma-of-fellowship-training/44745/A roundtable discussion explores the benefits of nontraditional fellowships.Presbyopia Correction: Expanding the Market
https://crstoday.com/crst-issues/nov-dec-2021/presbyopia-correction-expanding-the-market/44603/A roundtable discussion.*The New Guard of Refractive Surgeons
https://crstoday.com/crst-issues/nov-dec-2021/the-new-guard-of-refractive-surgeons/44590/Three ophthalmologists in their first few years of practice reflect on their experiences.Utilizing the First Intracameral Steroid for Cataract Surgery
https://crstoday.com/crst-supplements/utilizing-the-first-intracameral-steroid-for-cataract-surgery/utilizing-the-first-intracameral-steroid-for-cataract-surgery/44244/At MillennialEYE Live, four pioneering surgeons discussed how DEXYCU (dexamethasone intraocular suspension) 9% is incorporated into cataract surgery.The Digital Revolution
https://crstoday.com/topics/cataract-surgery/the-digital-revolution/44268/Everything you need to know about 3D digital visualization platforms for digitally assisted cataract surgery.The Current State of Reimbursement
https://crstoday.com/topics/practice-management/the-current-state-of-reimbursement/44075/Two surgeons share their thoughts on insurance coverage from the past to the present.The Pros and Cons of Private Equity
https://crstoday.com/topics/practice-management/the-pros-and-cons-of-private-equity/43767/Recapitalization and access to capital straddle opposite ends of the private equity risk/benefit ratio.Boris Malyugin, MD, PhD
https://crstoday.com/topics/general/boris-malyugin-md-phd/43650/